The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
276 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $78,544,505 in first-year total cost, median $230,617.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-A (M1)]13
- Special Emphasis Panel[ZCA1 SRB-P (M2)]13
- Special Emphasis Panel[ZCA1 SRB-A (O1)]12
- Special Emphasis Panel[ZCA1 SRB-X (M2)]12
- Special Emphasis Panel[ZCA1 SRB-K (J1)]10
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR13
- UNIVERSITY OF ALABAMA AT BIRMINGHAM8
- RESEARCH INST OF FOX CHASE CAN CTR7
- UNIVERSITY OF CALIFORNIA LOS ANGELES7
- H. LEE MOFFITT CANCER CTR & RES INST6
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Targeting p300/CBP in renal cell carcinoma1R21CA296705-01A1 | KOLENKO, VLADIMIR M | RESEARCH INST OF FOX CHASE CAN CTR, PA | $483,395 | ZCA1 |
| 2025 | pA-regulator controlled, JMJD6 reprogrammed GPC3-CAR T cells for patients with hepatocellular carcinoma1R21CA299361-01 | HECZEY, ANDRAS A.YEN, LAISING LEWIS | SEATTLE CHILDREN'S HOSPITAL, WA | $470,759 | ZCA1 |
| 2025 | Determinants of PARP-inhibitor response in Breast Cancer Patients without germline mutations in BRCA1/21R21CA303219-01 | WULF, GERBURG M | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $470,567 | ZCA1 |
| 2025 | Electronic Nose Technology to Predict and Assess Pathologic Response After Neoadjuvant Therapy and Recurrence for Non-Small Cell Lung Cancer1R21CA299070-01 | ROCCO, GAETANO | SLOAN-KETTERING INST CAN RESEARCH, NY | $452,540 | ZCA1 |
| 2025 | Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer1R21CA302807-01 | NEEL, BENJAMIN G. | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $435,827 | ZCA1 |
| 2025 | A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain1R21CA303409-01 | PFLEGER, CATHIE M | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $434,542 | ZCA1 |
| 2025 | Developing Multispecific T cell Engaging Therapy for Mixed Phenotype Acute Leukemia1R21CA296748-01A1 | LOH, MIGNON LEE-CHEUNPRICE, JANET E. | SEATTLE CHILDREN'S HOSPITAL, WA | $434,361 | ZCA1 |
| 2025 | Exploring anti-sense RNAs in melanocyte transformation and melanoma formation1R21CA303007-01 | KARRETH, FLORIAN | H. LEE MOFFITT CANCER CTR & RES INST, FL | $433,256 | ZCA1 |
| 2025 | Extracellular vesicle enclosed circular RNA and interferon responses in tumor host interactions.1R21CA299812-01 | GUARNERIO, JLENIASILVA, TAYLON FELIPE | CEDARS-SINAI MEDICAL CENTER, CA | $429,399 | ZCA1 |
| 2025 | Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study1R21CA292276-01A1 | VIJAYVERGIA, NAMRATAWARD, SARA J | RESEARCH INST OF FOX CHASE CAN CTR, PA | $429,162 | ZCA1 |
| 2025 | Cross-talk between social determinants of health and MTOR pathway, the missing link in fatigue1R21CA288925-01A1 | GONZALEZ-MERCADO, VELDA JANET | NEW YORK UNIVERSITY, NY | $427,085 | ZCA1 |
| 2025 | DNA Methylation Markers for early detection and monitoring the trajectory of tumor burden in Bladder Cancer1R21CA296470-01A1 | DANESHMAND, SIAMAKLIANG, GANGNING | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $426,828 | ZCA1 |
| 2025 | Multi-omics & AI-based imaging to identify biomarkers of molecular targets for breast cancer prevention1R21CA291905-01A1 | MODUGNO, FRANCESMARY | MAGEE-WOMEN'S RES INST AND FOUNDATION, PA | $425,573 | ZCA1 |
| 2025 | Therapeutic targeting and biophysical characterization of CAR-mediated trogocytosis1R21CA297125-01A1 | LUETKENS, TIMUPADHYAYA, ARPITA | UNIVERSITY OF MARYLAND BALTIMORE, MD | $422,799 | ZCA1 |
| 2025 | Targeting a Novel Secreted Immune Checkpoint to Enhance Liver Cancer Immunotherapy1R21CA302797-01 | DENG, YALAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $421,685 | ZCA1 |
| 2025 | Exploratory studies of cellular resistance to MTA-cooperative PRMT5 inhibitors in MTAP-loss tumors.1R21CA296234-01A1 | AHNERT, JORDI RODONBEDFORD, MARK T.XU, HAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $420,400 | ZCA1 |
| 2025 | Leveraging combination histotripsy tumor ablation and N-dihydrogalactochitosan immunostimulation to advance osteosarcoma therapy1R21CA296742-01A1 | TUOHY, JOANNE | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $419,080 | RTB |
| 2025 | Improving CAR-T cell therapy in metastatic breast cancers by reprogramming obesity-aggravated tumor microenvironment via physical activity1R21CA302986-01 | FUKUMURA, DAI | MASSACHUSETTS GENERAL HOSPITAL, MA | $416,818 | ZCA1 |
| 2025 | Boosting Oncolytic HSV Immunotherapy by Enabling Necroptosis1R21CA303392-01 | GUO, HONGYAN | LOUISIANA STATE UNIV HSC SHREVEPORT, LA | $416,040 | ZCA1 |
| 2025 | Harnessing B Cells after Stem Cell Transplant to Produce Novel CAR-Ts1R21CA302979-01 | SARANTOPOULOS, STEFANIE | DUKE UNIVERSITY, NC | $415,257 | ZCA1 |
| 2025 | Directed evolution of TCRs with improved antigen sensitivity1R21CA305319-01 | BIRNBAUM, MICHAEL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $414,803 | ZCA1 |
| 2025 | CCNE1 is synthetically lethal with drug induced nuclear Cathepsin L (nCTSL)1R21CA302968-01 | SHRIDHAR, VIJI | MAYO CLINIC ROCHESTER, MN | $412,429 | ZCA1 |
| 2025 | Using Vagal Nerve Stimulation in Conjunction with NRT for Smoking Cessation1R21CA302802-01 | CROGHAN, IVANA TALLERICOHURT, RYAN THOMAS | MAYO CLINIC ROCHESTER, MN | $411,939 | ZCA1 |
| 2025 | GENES WITH SIGNIFICANT DEFICIT OF LOSS-OF-FUNCTION MUTATIONS IN LUNG TUMOR1R21CA291676-01A1 | GORLOV, IVAN P | BAYLOR COLLEGE OF MEDICINE, TX | $411,404 | ZCA1 |
| 2025 | Noncovalent interaction of mutant KRAS inhibitors1R21CA297690-01A1 | CHI, JEN-TSAN ASHLEY | DUKE UNIVERSITY, NC | $411,152 | ZCA1 |
| 2025 | Enhancing anti-PD-1 blockade antitumor efficacy by oncolytic virotherapy-mediated tumor microenvironment immunomodulation1R21CA302730-01 | GOMEZ-GUTIERREZ, JORGE G | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $409,158 | ZCA1 |
| 2025 | Develop positive allosteric modulators to enhance XCR1 signaling in cancer1R21CA299543-01 | ZHANG, CHENG | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $408,829 | ZCA1 |
| 2025 | Harnessing Phosphorus Fluoride Exchange (PFEx) Click Chemistry for Developing Covalent Anti-Cancer Drugs1R21CA303396-01 | YU, BINGCHEN | GEORGIA STATE UNIVERSITY, GA | $406,258 | ZCA1 |
| 2025 | Targeting tumor microenvironment-mediated radiopharmaceutical therapy resistance in prostate cancer1R21CA303173-01 | ABT, EVAN ROBERTMONA, CHRISTINE E | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $404,972 | ZCA1 |
| 2025 | Development of new Pt-based ROS storm inducing polymers with tumor specific toxicity1R21CA292295-01A1 | MAI, JUNHUA | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $403,485 | ZCA1 |
| 2025 | Cognitive behavioral theory-assisted virtual reality for chronic cancer pain (VR-CAN): device prototype development and feasibility testing1R21CA299799-01 | GRONINGER, J. HUNTERKELLEHER, SARAH | MEDSTAR HEALTH RESEARCH INSTITUTE, MD | $403,383 | ZCA1 |
| 2025 | Targeting CXCR2+ PMN-MDSCs for immunotherapy of hepatoblastoma1R21CA292251-01A1 | CHEN, XIN | UNIVERSITY OF HAWAII AT MANOA, HI | $402,400 | ZCA1 |
| 2025 | Contrast-enhanced ultrasound evaluation of radioembolization treatment response1R21CA303648-01 | EISENBREY, JOHN | THOMAS JEFFERSON UNIVERSITY, PA | $401,115 | ZCA1 |
| 2025 | New models for interrogating the impact of sex chromosomes and sex hormones on glioblastoma1R21CA296713-01A1 | IPPOLITO, JOSEPH EDWARD | WASHINGTON UNIVERSITY, MO | $399,829 | ZCA1 |
| 2025 | Targeting DDX3 for triple-negative breast cancer treatment1R21CA295917-01A1 | RAMAN, VENU | JOHNS HOPKINS UNIVERSITY, MD | $399,129 | ZCA1 |
| 2025 | Development of deazaflavin analogs as potent and selective MRP1 inhibitors for cancer chemosensitization1R21CA303454-01 | WANG, ZHENGQIANGXIE, JIASHU | UNIVERSITY OF MINNESOTA, MN | $395,973 | ZCA1 |
| 2025 | Mechanism and pathways of Glucocorticoid Receptor (GR) signaling in TNBC progression1R21CA296504-01A1 | RIEGEL, ANNA TATE | GEORGETOWN UNIVERSITY, DC | $395,356 | ZCA1 |
| 2025 | Enhancing antitumor efficacy by intratumoral delivering LAIR1 inhibitory signaling1R21CA288943-01A1 | HUANG, JIANPING | UNIVERSITY OF FLORIDA, FL | $394,687 | ZCA1 |
| 2025 | LAT1 as a Novel Therapeutic Target in Colorectal Cancer1R21CA292205-01A1 | SUBRAMANIAN, SUBBAYA | UNIVERSITY OF MINNESOTA, MN | $394,532 | ZCA1 |
| 2025 | Therapeutic co-targeting of LGR5 and MET to overcome heterogeneity and therapy resistance in colorectal tumors1R21CA302991-01 | CARMON, KENDRA S. | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $393,872 | ZCA1 |
| 2025 | Co-targeting IGF-1R and Glutaminase in Ewing Sarcoma1R21CA297629-01A1 | BAND, HAMID | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $391,186 | ZCA1 |
| 2025 | Biologic rationale of fallopian tube removal to prevent uterine serous carcinoma1R21CA292343-01A1 | DELANEY, JOE R | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $388,256 | ZCA1 |
| 2025 | Preclinical development and validation of targeted mass spectrometry assays for serous ovarian cancer diagnosis1R21CA288922-01A1 | THOMAS, STEFANI | UNIVERSITY OF MINNESOTA, MN | $386,700 | ZCA1 |
| 2025 | Advanced Dual-Nuclei MRI for Differentiation of Recurrent Brain Metastases and Radiation Necrosis1R21CA303383-01 | KIM, WONYAO, JINGWEN | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $382,449 | ZCA1 |
| 2025 | Combining c-Myc inhibitor and SHetA2 for cervical cancer: A promising low-to-no toxicity therapeutic strategy1R21CA296216-01A1 | RAI, RAJANI | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $376,490 | ZCA1 |
| 2025 | A Pilot Study to Correlate 4-[18F]fluoro-1-naphthol PET/CT Imaging with Chronic Graft Versus Host Disease Manifestations1R21CA303350-01 | CHEN, GEORGE LIWEIPIWNICA-WORMS, DAVID | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $358,605 | ZCA1 |
| 2025 | Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical release1R21CA296712-01 | MOSES, JOHN EDWARD | COLD SPRING HARBOR LABORATORY, NY | $269,280 | ZCA1 |
| 2025 | Targeting cellular senescense in pancreatic cancer1R21CA299593-01 | HAN, HAIYONG | TRANSLATIONAL GENOMICS RESEARCH INST, AZ | $269,280 | ZCA1 |
| 2025 | Immune Checkpoint Blockade Targeting the Novel PSGL-1/VISTA Axis for Pancreatic Cancer1R21CA293150-01A1 | BRADLEY, LINDA MAC PHERSON | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $268,345 | ZCA1 |
| 2025 | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors1R21CA295906-01 | LISSANU, YONATHAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $267,527 | ZCA1 |
| 2025 | Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma1R21CA296230-01 | VISWANATHAN, SRINIVAS RAGHAVAN | DANA-FARBER CANCER INST, MA | $267,298 | ZCA1 |
| 2025 | Multiparametric endoscopic ultrasound for improved pancreatic cancer screening and characterization1R21CA296688-01 | BURGESS, MARK THOMAS | SLOAN-KETTERING INST CAN RESEARCH, NY | $263,086 | ZCA1 |
| 2025 | Advanced Genetic Engineering to Unravel Tumor-Specific B Cell Responses1R21CA296527-01 | GENOVESE, PIETRO | BOSTON CHILDREN'S HOSPITAL, MA | $249,645 | ZCA1 |
| 2025 | Characterizing the autologous fat graft microenvironment resulting from differential intraoperative processing techniques: A comparative analysis and its clinical implications1R21CA287340-01A1 | BROWN, KRISTY A.OTTERBURN, DAVID | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $247,660 | ZCA1 |
| 2025 | Integrating Radiologist Insights for Safe and Accurate AI-Assisted Prostate MRI Interpretation1R21CA301093-01 | AKIN, OGUZPENG, XI | UNIVERSITY OF DELAWARE, DE | $245,087 | ZCA1 |
| 2025 | Focused Ultrasound and CAR T Cells for Pediatric Brain Malignancies1R21CA292273-01A1 | HAYDAR, DALIASHEYBANI, NATASHA DIBA | UNIVERSITY OF VIRGINIA, VA | $244,839 | ZCA1 |
| 2025 | Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer1R21CA288901-01A1 | GIRARD, LUCLI, JUNLIANG, HAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $244,228 | ZCA1 |
| 2025 | Novel biologic therapeutics targeting vacuolar ATPase localized on plasma membrane1R21CA292032-01A1 | BAR-SAGI, DAFNAKOIDE, SHOHEI | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $237,724 | ZCA1 |
| 2025 | Precision use of radiation for in situ cancer immunization1R21CA292282-01A1 | DEMARIA, SANDRA | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $237,724 | ZCA1 |
| 2025 | Somatostatin Receptor 2 Expression in Pituitary Neuroendocrine Tumors as a Basis for PET/MRI guided Subtype Stratification and Radiotherapy Planning1R21CA289111-01A1 | IVANIDZE, JANAKNISELY, JONATHAN P.S. | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $235,707 | ZCA1 |
| 2025 | Prevention and Therapy of Inflammation Associated Colorectal Cancer1R21CA295643-01 | AUGENLICHT, LEONARD H | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $235,620 | ZCA1 |
| 2025 | Guadecitabine-directed immune regulation in targeting prostate cancer1R21CA292333-01A1 | KARAN, DEV | UNIVERSITY OF LOUISVILLE, KY | $234,889 | ZCA1 |
| 2025 | Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung Cancer1R21CA299786-01 | HUANG, XIAOPEIOWEN, DWIGHT H. | OHIO STATE UNIVERSITY, OH | $234,749 | ZCA1 |
| 2025 | Targeting Tumor-Driven Immune Tolerance to Overcome Resistance to Hedgehog Inhibition1R21CA301201-01 | KIM, ARIANNA L | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $230,711 | ZCA1 |
| 2025 | Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based Approach1R21CA299377-01 | CHEN, JOYCE HUANHUAN | UNIVERSITY OF CHICAGO, IL | $230,010 | ZCA1 |
| 2025 | Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses1R21CA283514-01A1 | FUEYO, JUANGOMEZ-MANZANO, CANDELARIA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $229,309 | ZCA1 |
| 2025 | Photofrin dark effects and heme oxygenase inducers as therapeutic in mesothelioma1R21CA286282-01A1 | BUSCH, THERESA M | UNIVERSITY OF PENNSYLVANIA, PA | $227,906 | ZCA1 |
| 2025 | Inhibition of diacylglycerol lipase α as a novel strategy to mitigate the nephrotoxicity of cisplatin1R21CA289216-01A1 | LI, NINGJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $227,221 | ZCA1 |
| 2025 | Tobacco use trajectories and related mechanisms among US adults and youth representing minority and intersecting minority identities1R21CA292195-01A1 | BERG, CARLA JWANG, YAN | GEORGE WASHINGTON UNIVERSITY, DC | $226,504 | ZCA1 |
| 2025 | Evaluating Maintenance In Light chain Amyloidosis (EMILIA)1R21CA288898-01A1 | KOURELIS, TAXIARCHIS | MAYO CLINIC ROCHESTER, MN | $226,435 | ZCA1 |
| 2025 | Mechanisms underlying increased risk of hematological malignancy in sickle cell disease.1R21CA299166-01 | MALIK, PUNAM | CINCINNATI CHILDRENS HOSP MED CTR, OH | $225,101 | ZCA1 |
| 2025 | MYCN drives a suppressive tumor immune microenvironment in neuroblastoma.1R21CA300631-01 | BARBIERI, EVELINE | BAYLOR COLLEGE OF MEDICINE, TX | $225,101 | ZCA1 |
| 2025 | Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapies against cancer1R21CA296693-01 | RIVADENEIRA, DAYANA | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $222,998 | ZCA1 |
| 2025 | Cancer therapy by targeting innate immune cells in vivo using novel virus-like particles1R21CA289083-01A1 | KAUFMAN, DAN S. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $222,998 | ZCA1 |
| 2025 | Identifying novel targets for cancer using high throughput deformability screening1R21CA289090-01A1 | ROWAT, AMY C | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $220,894 | ZCA1 |
| 2025 | Elucidate the role and mechanism of IFNε in Kras-driven lung tumorigenesis1R21CA288674-01A1 | CHANG, THERESA LGUO, YANXIANG | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $220,193 | ZCA1 |
| 2025 | Mitochondrial regulation of chemotherapy-induced reactive myelopoiesis and pro-metastatic effects1R21CA288604-01A1 | DING, CHUANLIN | UNIVERSITY OF LOUISVILLE, KY | $220,018 | ZCA1 |
| 2025 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt61R21CA288808-01A1 | HAMAIDI, IMENE | MAYO CLINIC JACKSONVILLE, FL | $219,491 | ZCA1 |
| 2025 | ECT2 Isoform Switch in Pancreatic Cancer.1R21CA296671-01 | JUSTILIEN, VERLINE | MAYO CLINIC JACKSONVILLE, FL | $219,491 | ZCA1 |
| 2025 | Mapping the origin of HER2 plasticity in breast cancer1R21CA286273-01A1 | SPANGLE, JENNIFER MARIE | EMORY UNIVERSITY, GA | $219,491 | ZCA1 |
| 2025 | Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment1R21CA296696-01 | YANG, ZENG-JIE | RESEARCH INST OF FOX CHASE CAN CTR, PA | $219,351 | ZCA1 |
| 2025 | CSP7 inhibits toxicity of ionizing radiation to the lung1R21CA282561-01A1 | SHETTY, SREERAMA | UNIVERSITY OF TEXAS HLTH CTR AT TYLER, TX | $219,024 | ZCA1 |
| 2025 | Mechanism and treatment of Wilms Tumors caused by CTR9 mutations1R21CA295443-01 | XU, WEI | UNIVERSITY OF WISCONSIN-MADISON, WI | $218,089 | ZCA1 |
| 2025 | Novel Immunotherapy Targeting Local and Systemic Immunity for Treatment of Ocular Surface Squamous Neoplasia1R21CA289152-01A1 | DOW, STEVEN W. | COLORADO STATE UNIVERSITY, CO | $215,985 | ZCA1 |
| 2025 | Alleviating stress, loneliness, and social isolation among South Asian families managing breast cancer1R21CA292256-01A1 | TRIVEDI, RANAK | STANFORD UNIVERSITY, CA | $215,985 | ZCA1 |
| 2025 | Exosome Signatures of Kidney Cancer Response to Immune Checkpoint Inhibitor1R21CA299766-01 | FAN, ALICE CHEN | STANFORD UNIVERSITY, CA | $215,985 | ZCA1 |
| 2025 | Preclinical efficacy of GPR56 antibody-drug conjugates and combination therapies for triple-negative breast cancer1R21CA291788-01A1 | CARMON, KENDRA S. | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $215,311 | ZCA1 |
| 2025 | Evaluation of a triple negative matrix signature in tumor progression and resistance1R21CA286211-01A1 | MARTIN, ELIZABETH | TULANE UNIVERSITY OF LOUISIANA, LA | $214,583 | ZCA1 |
| 2025 | Contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy1R21CA297068-01 | SHIOZAWA, YUSUKE | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $213,480 | ZCA1 |
| 2025 | Characterize the metabolic landscape of ARID1A-mutated ovarian cancer1R21CA287351-01A1 | BAZZARO, MARTINATHOMAS, STEFANI | UNIVERSITY OF MINNESOTA, MN | $212,013 | ZCA1 |
| 2025 | A Dkk-1 targeting antisense therapy for human osteosarcoma, developed with help from man’s best friend1R21CA286523-01A1 | GREGORY, CARL A. | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX | $210,789 | ZCA1 |
| 2025 | A Novel Approach to Enhance Therapeutic Efficacy of Tarlatamab for Small Cell Lung Cancer Treatment1R21CA298890-01 | WAJAPEYEE, NARENDRA | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $208,271 | ZCA1 |
| 2025 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response1R21CA292178-01A1 | YAEGER, RONA | SLOAN-KETTERING INST CAN RESEARCH, NY | $205,700 | ZCA1 |
| 2025 | Modifying the Single Domain Antibody Framework as Platform for Enhanced Radiotherapy1R21CA297395-01 | LARIMER, BENJAMIN M | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $205,621 | ZCA1 |
| 2025 | Advanced PET/MRI to quantify heterogeneity of HER2 and vasculature in HER2+ breast-to-brain metastasis prior to combination targeted and radiotherapy1R21CA289166-01A1 | SORACE, ANNA C | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $204,295 | ZCA1 |
| 2025 | RANK Signaling Inhibitors for Osteolytic Lesions in Multiple Myeloma1R21CA296500-01 | FENG, XU | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $201,609 | ZCA1 |
| 2025 | DISSECTING THE ROLE OF THE IMMUNE MICROENVIRONMENT IN MELANOMA BONE METASTASIS1R21CA297650-01 | HERNANDO, EVA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $198,103 | ZCA1 |
| 2025 | Development of a Clinically Relevant Genetically Engineered Mouse Model for Human High-Risk Rhabdomyosarcoma1R21CA286286-01A1 | TAO, JIANNING | SANFORD RESEARCH/USD, SD | $194,013 | ZCA1 |
| 2025 | Development of a new tool to treat small cell lung cancer1R21CA301276-01 | OFFRINGA, ITE A | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $194,013 | ZCA1 |
| 2025 | Jumonji KDM4A drives targetable oncogenic programs in small cell lung cancer1R21CA280319-01A1 | MARTINEZ, ELISABETH D | UT SOUTHWESTERN MEDICAL CENTER, TX | $191,675 | ZCA1 |
| 2025 | Characterization of KSHV-Associated Disease Specific Gene Therapy1R21CA299587-01 | IZUMIYA, YOSHIHIRO | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $188,169 | ZCA1 |
| 2025 | Lipid-initiated epigenetic reprogramming of the breast to a neural phenotype1R21CA288676-01A1 | CLARE, SUSAN E. | NORTHWESTERN UNIVERSITY, IL | $187,000 | ZCA1 |
| 2025 | Discovery and Development of Allosteric Inhibitors of Src-family Kinases for AML1R21CA291724-01A1 | SMITHGALL, THOMAS E. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $185,831 | ZCA1 |
| 2025 | Glyco-MAP: a high-throughput multiplexed platform for Glycosylated Mucin Antibody Profiling with glycoengineered cell lines expressing well-defined homogeneous glycostructures1R21CA296660-01A1 | QIU, JI | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS, AZ | $183,494 | ZCA1 |
| 2025 | Inhibition of NLRP3 inflammasome for the treatment of Chemotherapy-induced peripheral neuropathy1R21CA296516-01 | DAMAJ, M. IMAD | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $181,448 | ZCA1 |
| 2025 | Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain1R21CA298918-01 | DUAN, BINTRIPPIER, PAUL | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $179,403 | ZCA1 |
| 2025 | Co-stimulation of T cell responses to nascent, emerging tumors1R21CA286410-01A1 | BINDER, ROBERT J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $176,712 | ZCA1 |
| 2025 | Electrical impedance dermography as a biomarker for basal and squamous cell carcinoma1R21CA289101-01A1 | GROSSMAN, DOUGLASSANCHEZ TERRONES, BENJAMIN | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, UT | $174,939 | ZCA1 |
| 2025 | Monitoring CAR T Cell Therapeutic Response and Toxicity with Real-time, Label-free Cell Quantification1R21CA301006-01 | DIONNE, JENNIFER A. | STANFORD UNIVERSITY, CA | $170,376 | ZCA1 |
| 2025 | A BCR transgenic mouse model to study glycan-specific B cells1R21CA297692-01 | HAAS, KAREN M | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $169,329 | ZCA1 |
| 2025 | Identifying the effects of NRF2 signaling on lung squamous cell carcinoma development1R21CA292297-01A1 | MAJOR, MICHAEL BENJAMINWEISSMAN, BERNARD E. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $158,365 | ZCA1 |
| 2025 | Sequential infection of laboratory mice for enhanced cancer and immunotherapy translation1R21CA296062-01A1 | BROOKS, DAVID G | UNIVERSITY HEALTH NETWORK, ON | $138,846 | ZCA1 |
| 2024 | Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma models1R21CA292221-01 | OLSON, JAMES M | SEATTLE CHILDREN'S HOSPITAL, WA | $503,194 | ZCA1 |
| 2024 | A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer1R21CA286231-01A1 | MAKHOV, PETR B. | RESEARCH INST OF FOX CHASE CAN CTR, PA | $483,395 | ZCA1 |
| 2024 | Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer1R21CA282851-01A1 | BODOR, JOSEPH NICHOLAS | RESEARCH INST OF FOX CHASE CAN CTR, PA | $483,395 | ZCA1 |
| 2024 | Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer1R21CA286342-01A1 | ABRAMS, SCOTT I.IONOV, YURIJ | ROSWELL PARK CANCER INSTITUTE CORP, NY | $460,977 | ZCA1 |
| 2024 | Targeting Tregs in the solid tumor microenvironment by modulating metabolite signaling1R21CA280643-01A1 | KINSELLA, SINÉAD | FRED HUTCHINSON CANCER CENTER, WA | $452,544 | ZCA1 |
| 2024 | MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer1R21CA289134-01 | KUFE, DONALD W. | DANA-FARBER CANCER INST, MA | $450,429 | ZCA1 |
| 2024 | Using patient-derived co-culture models of breast cancer to develop new treatment strategies targeting succinate signaling.1R21CA292302-01 | MURANEN, TARU ELIISA | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $444,569 | ZCA1 |
| 2024 | Adapting and testing a smoking cessation intervention for transgender and gender-diverse individuals1R21CA292185-01 | O'CLEIRIGH, CONALL MICHAELSTANTON, AMELIA M. | MASSACHUSETTS GENERAL HOSPITAL, MA | $439,966 | ZCA1 |
| 2024 | Targeting a PHGDH metabolic vulnerability in melanoma1R21CA289213-01 | KARRETH, FLORIAN | H. LEE MOFFITT CANCER CTR & RES INST, FL | $433,256 | ZCA1 |
| 2024 | Lipid-Rich Macrophages at the Tumor-Adipose Interface: A New Target for Locally-Invasive Prostate Cancer Therapy1R21CA291898-01 | HAYWARD, SIMON W | ENDEAVOR HEALTH CLINICAL OPERATIONS, IL | $433,157 | ZCA1 |
| 2024 | Monitoring Listeria in vivo using 18FDG and PET scan1R21CA292190-01 | GRAVEKAMP, CLAUDIA | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $431,970 | ZCA1 |
| 2024 | Hijacking Post-translational Arginylation for Targeted Protein Degradation1R21CA292191-01 | LIN, ZONGTAOLYU, DONGWEN | WASHINGTON UNIVERSITY, MO | $425,587 | ZCA1 |
| 2024 | Unraveling Vascular Mediated Immune Exclusion in Melanoma1R21CA293766-01 | KIM, MINAH | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $422,971 | ZCA1 |
| 2024 | Frontiers in Bone Metastatic Models for Prostate Cancer1R21CA282396-01A1 | BERKMAN, CLIFFORDCAROMILE, LESLIE ANN | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $422,874 | ZCA1 |
| 2024 | Enabling a rapid transition from synthase to structure1R21CA280558-01A1 | BURKART, MICHAEL D.EUSTAQUIO, ALESSANDRA S | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $422,036 | ZCA1 |
| 2024 | Inhibition of pleiotrophin to combat pancreatic cancer metastasis1R21CA286348-01A1 | BREKKEN, ROLF A | UT SOUTHWESTERN MEDICAL CENTER, TX | $421,685 | ZCA1 |
| 2024 | A study of IDH1-mutant prostate cancer to identify novel therapeutic targets1R21CA292179-01 | SENA, LAURA A. | JOHNS HOPKINS UNIVERSITY, MD | $421,042 | ZCA1 |
| 2024 | Enhancing CAR-T cell therapy through theranostic targeted radionuclide therapy1R21CA292224-01 | JIN, MOONSOO M.YANG, YANPING | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $415,260 | ZCA1 |
| 2024 | Targeting metabolic stress response to improve CAR-T cell efficacy.1R21CA280566-01A1 | MIN, IRENE M. | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $415,257 | ZCA1 |
| 2024 | Development of a pre-clinical syngeneic pig glioma model for research and translational studies1R21CA287157-01A1 | HORNER, PHILIP JROSTOMILY, ROBERT CVISHNOI, MONIKA | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $415,257 | ZCA1 |
| 2024 | The urinary microbiome and bladder toxicity after pelvic radiotherapy1R21CA280170-01A1 | GILL, STEVEN R.KERNS, SARAH L.MARPLES, BRIAN | UNIVERSITY OF ROCHESTER, NY | $414,781 | ZCA1 |
| 2024 | Investigating a Novel Inhibitory Receptor in Regulating CAR-T Cell Persistence and Function1R21CA286304-01A1 | WANG, LI LILY | CLEVELAND CLINIC LERNER COM-CWRU, OH | $413,971 | ZCA1 |
| 2024 | Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic Leukemia1R21CA286412-01A1 | LACORAZZA, DANIEL | BAYLOR COLLEGE OF MEDICINE, TX | $412,685 | ZCA1 |
| 2024 | Explore piRNAs as a novel group of biomarkers for ovarian cancer early detection1R21CA277412-01A1 | ZHU, YONG | UNIV OF ARKANSAS FOR MED SCIS, AR | $411,876 | ZCA1 |
| 2024 | Nanoparticle-coated macrophages for targeted disruption of YAP/TEAD interactions in breast cancer brain metastasis1R21CA291723-01 | ER, EKREM EMRAHZHAO, ZONGMIN | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $411,143 | ZCA1 |
| 2024 | Targeted nanotherapies for the treatment of prostate cancer1R21CA286235-01A1 | SHARMA, ANJALI | WASHINGTON STATE UNIVERSITY, WA | $406,520 | ZCA1 |
| 2024 | Circadian regulation of astrocytic adenosine kinase in the irradiated and cancer brain1R21CA292148-01 | ACHARYA, MUNJAL MMAHAN, KRISTIN ECKEL | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $406,217 | ZCA1 |
| 2024 | Investigating KIF20A as a therapeutic target in glioblastoma1R21CA271217-01A1 | SUMMERS, MATTHEW KVENERE, MONICA | OHIO STATE UNIVERSITY, OH | $404,974 | ZCA1 |
| 2024 | Develop universal CAR macrophage cell therapy for pancreatic cancer1R21CA286398-01A1 | HOU, PINGPING | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $403,687 | ZCA1 |
| 2024 | High-throughput assessment of chemotherapy-induced cardiotoxicity in 3D human cardiomyocytes1R21CA285254-01A1 | XU, CHUNHUI | EMORY UNIVERSITY, GA | $402,403 | ZCA1 |
| 2024 | Development of a PET CCR2 Imaging Agent to Profile PDAC Microenvironment1R21CA286283-01A1 | GOODMAN, MARK MYRONLESINSKI, GREGORY B. | EMORY UNIVERSITY, GA | $402,401 | ZCA1 |
| 2024 | Pilot testing of metacognitive strategy training to address cancer-related cognitive impairment in breast cancer1R21CA286404-01A1 | BOONE, ANNAFROELIGER, BRETTWOLF, TIMOTHY J. | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $402,401 | ZCA1 |
| 2024 | Understanding and overcoming resistance of breast cancer brain metastases to RET inhibition1R21CA286225-01A1 | LO, HUI-WEN | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $401,115 | ZCA1 |
| 2024 | S1PR1-targeted PET imaging to predict and monitor response to HER2-targeting antibody-drug conjugates1R21CA291680-01 | RIBEIRO PEREIRA, PATRICIA MANUELATU, ZHUDE | WASHINGTON UNIVERSITY, MO | $399,829 | ZCA1 |
| 2024 | A generalizable model of normal tissue recovery to enable personalized re-irradiation1R21CA292207-01 | GRASSBERGER, CLEMENS | UNIVERSITY OF WASHINGTON, WA | $399,829 | ZCA1 |
| 2024 | Augmenting focused ultrasound-mediated drug delivery to brain tumors with vascular normalization1R21CA286367-01A1 | PRICE, RICHARD J. | UNIVERSITY OF VIRGINIA, VA | $399,294 | ZCA1 |
| 2024 | Modeling Marginal Zone Lymphomagenesis1R21CA270930-01A1 | YAZBECK, VICTOR | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $399,187 | ZCA1 |
| 2024 | Stress, inflammation, and health-related quality of life of long-term breast cancer survivors1R21CA290430-01 | JOHN, ESTHER M. | STANFORD UNIVERSITY, CA | $396,543 | ZCA1 |
| 2024 | Assessment of a recently developed boron-based HIF inhibitor as a prospective therapy for renal cell carcinoma (RCC)1R21CA292298-01 | MUKHERJI, MRIDUL | UNIVERSITY OF MISSOURI KANSAS CITY, MO | $396,061 | ZCA1 |
| 2024 | Targeting Senescence and the senescent secretome to impact breast cancer formation1R21CA286419-01A1 | KORKOLA, JAMES | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $395,973 | ZCA1 |
| 2024 | Tumor-Activated Dual Payload-Drug Conjugates1R21CA292338-01 | BERKMAN, CLIFFORD | WASHINGTON STATE UNIVERSITY, WA | $393,401 | ZCA1 |
| 2024 | Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells1R21CA292278-01 | KOSS, BRIANTACKETT, ALAN | UNIV OF ARKANSAS FOR MED SCIS, AR | $393,401 | ZCA1 |
| 2024 | ILT3 (LILRB4) in anti-tumor immunity and immunotherapy1R21CA273885-01A1 | COLONNA, MARCO | WASHINGTON UNIVERSITY, MO | $391,277 | ZCA1 |
| 2024 | MAIT cells as a therapeutic approach for gastrointestinal cancers1R21CA280224-01A1 | BESWICK, ELLEN J.LEUNG, DANIEL TED | UNIVERSITY OF UTAH, UT | $384,092 | ZCA1 |
| 2024 | Spatial stromal proteomic biosignatures of DCIS risk and progression1R21CA286287-01A1 | ANGEL, PEGGI M | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $380,057 | ZCA1 |
| 2024 | Combination optical imaging to guide transoral laser microsurgery in larynx cancer1R21CA292196-01 | PANUGANTI, BHARATWARRAM, JASON MORGAN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $374,880 | ZCA1 |
| 2024 | Preclinical Efficacy of Allogeneic and Human Silicified Cancer Vaccines1R21CA282618-01A1 | SERDA, RITA ELENA | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | $356,469 | ZCA1 |
| 2024 | Pilot in vivo trial with T-cell-based delivery of immunostimulatory proteins1R21CA288900-01 | RADHAKRISHNAN, HARIKRISHNAN | SRI INTERNATIONAL, CA | $293,028 | ZCA1 |
| 2024 | Identifying non-cardiotoxic drug combinations for patients with relapsed sarcoma1R21CA280139-01A1 | LAWLOR, ELIZABETH R | SEATTLE CHILDREN'S HOSPITAL, WA | $276,152 | ZCA1 |
| 2024 | In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity1R21CA286345-01 | MARASCO, WAYNE A. | DANA-FARBER CANCER INST, MA | $268,059 | ZCA1 |
| 2024 | A multimodal single-cell approach to developing personalized combinatorial treatments for glioblastoma1R21CA286215-01 | PETTI, ALLEGRA ADELE | MASSACHUSETTS GENERAL HOSPITAL, MA | $249,832 | ZCA1 |
| 2024 | Targeting alloantigen presentation in bone marrow to enhance graft-versus-leukemia effects1R21CA286216-01 | KOYAMA, MOTOKO | FRED HUTCHINSON CANCER CENTER, WA | $246,840 | ZCA1 |
| 2024 | Harnessing Cytomegalovirus (CMV)-specific T-cells for pancreatic cancer immunotherapy1R21CA286198-01 | BENEDICT, CHRISTOPHER AHURTADO DE MENDOZA, TATIANA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $242,178 | ZCA1 |
| 2024 | CAR mast cell for solid tumor1R21CA286364-01 | SU, XIAOLEI | YALE UNIVERSITY, CT | $241,713 | ZCA1 |
| 2024 | Cardiopulmonary function and cerebral blood flow in Hodgkin Lymphoma survivors1R21CA280230-01A1 | PHILLIPS, NICHOLAS S | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $239,921 | ZCA1 |
| 2024 | Targeting the Androgen Receptor to Sensitize Bladder Cancer to Immune Check Point Blockade.1R21CA286309-01 | MULHOLLAND, DAVID | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $237,023 | ZCA1 |
| 2024 | L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity1R21CA286226-01 | LAU, ERIC KIRK | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2024 | Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers1R21CA288927-01 | LOPCHUK, JUSTIN MATTHEWSCHONBRUNN, ERNST | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2024 | Adipose Tissue Reprograms Acute Lymphoblastic Leukemia Cells to Facilitate CNS and Bone Invasion1R21CA289085-01 | MITTELMAN, STEVEN DAVIDORGEL, ETAN | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $236,073 | ZCA1 |
| 2024 | Defining signatures of epigenetic sensitization to lung cancer in a mouse model1R21CA288677-01 | LESCH, BLUMA J | YALE UNIVERSITY, CT | $234,730 | ZCA1 |
| 2024 | Response assessment of glioblastoma using magnetic resonance elastography1R21CA282393-01A1 | DENG, BINGERSTNER, ELIZABETH | MASSACHUSETTS GENERAL HOSPITAL, MA | $234,218 | ZCA1 |
| 2024 | Using DNA Methylation Markers for Diagnosis and Prognosis of Upper Tract Urothelial Carcinoma1R21CA288920-01 | DJALADAT, HOOMANLIANG, GANGNING | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $232,640 | ZCA1 |
| 2024 | Enhancing Tumor Cell Immunogenicity using Improved Molecules Targeting Chromatin Remodeling1R21CA277437-01A1 | LANDRY, JOSEPH WILLIAMPOMERANTZ, WILLIAM CHARLES KRAUSE | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $230,523 | ZCA1 |
| 2024 | Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer1R21CA270591-01A1 | LIN, JIAYUH | UNIVERSITY OF MARYLAND BALTIMORE, MD | $230,361 | ZCA1 |
| 2024 | Exosome-mediated therapy for liver cancer1R21CA280232-01A1 | KRAITCHMAN, DARA L | JOHNS HOPKINS UNIVERSITY, MD | $229,659 | ZCA1 |
| 2024 | Monitoring response of neoadjuvant therapy in primary bladder cancer using hyperpolarized 13C MRI1R21CA288687-01 | SRIRAM, RENUKA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $229,134 | ZCA1 |
| 2024 | Cheminformatics-based identification of leukemia-targeting molecules1R21CA280500-01A1 | KIRIENKO, NATASHA | RICE UNIVERSITY, TX | $227,612 | ZCA1 |
| 2024 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors1R21CA277152-01A1 | CHEN, TAIPINGCHENG, XIAODONG | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2024 | A novel uterine leiomyosarcoma mouse model for therapeutic development1R21CA273661-01A1 | WONG, KWONG KWOK | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2024 | Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H11R21CA286318-01 | XIAO, YIYU, DIHUA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2024 | Characterization and treatment of a novel model of radiation optic neuropathy using the tree shrew1R21CA286349-01 | DALVIN, LAUREN ARODDY, GAVIN W | MAYO CLINIC ROCHESTER, MN | $226,364 | ZCA1 |
| 2024 | Development of a novel, CNS-penetrant synthetic triterpenoid for pediatric high-grade glioma.1R21CA280426-01A1 | LETTERIO, JOHN JAMES | CASE WESTERN RESERVE UNIVERSITY, OH | $225,803 | ZCA1 |
| 2024 | Forging a new path with cyclin-dependent kinase inhibitors to treat epithelioid hemangioendothelioma1R21CA288673-01 | POBBATI, AJAYBABURUBIN, BRIAN P | CLEVELAND CLINIC LERNER COM-CWRU, OH | $225,803 | ZCA1 |
| 2024 | Expanding the targetable landscape in cancer with serine-targeting covalent ligands1R21CA280163-01A1 | ZHANG, ZIYANG | UNIVERSITY OF CALIFORNIA BERKELEY, CA | $225,101 | ZCA1 |
| 2024 | Discovery of chemoresistant tumor subclones in pediatric liver cancers1R21CA286257-01 | SUMAZIN, PAVEL | BAYLOR COLLEGE OF MEDICINE, TX | $225,084 | ZCA1 |
| 2024 | Developing inhibitor combinations through identification of drug tolerant cell populations1R21CA282428-01A1 | BENEVOLENSKAYA, ELIZAVETA V | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $224,260 | ZCA1 |
| 2024 | Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors1R21CA286402-01 | DRIES, RUBENHEAPHY, CHRISTOPHER M | BOSTON MEDICAL CENTER, MA | $223,377 | ZCA1 |
| 2024 | Detecting Reversal of Apoptosis in Cancer Cells in Mice1R21CA286284-01 | TANG, HO LAM | JOHNS HOPKINS UNIVERSITY, MD | $221,911 | ZCA1 |
| 2024 | Exploring the interaction of lipid metabolism with the hexosamine pathway and tumor growth1R21CA280452-01A1 | PAPANDREOU, IOANNA | OHIO STATE UNIVERSITY, OH | $220,894 | ZCA1 |
| 2024 | Developing TCR-T cell therapy in renal cell carcinoma1R21CA286389-01 | CHIOU, SHIN-HENGHINRICHS, CHRISTIAN | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $220,193 | ZCA1 |
| 2024 | Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells1R21CA286340-01 | ARAP, WADIHPASQUALINI, RENATA | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $220,193 | ZCA1 |
| 2024 | NPC1 as a novel therapeutic target in ccRCC1R21CA289161-01 | KOLENKO, VLADIMIR M | RESEARCH INST OF FOX CHASE CAN CTR, PA | $219,725 | ZCA1 |
| 2024 | Develop IL13Ra1 for diagnosis of early-stage mycosis fungoides1R21CA280445-01A1 | FUSCHIOTTI, PATRIZIAGESKIN, LARISA J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $218,886 | ZCA1 |
| 2024 | The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer1R21CA286372-01 | GALBAN, STEFANIEPASCA DI MAGLIANO, MARINA | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $218,790 | ZCA1 |
| 2024 | Ligand-Induced Recruitment of CAR-T Cells to Colorectal Cancers1R21CA286339-01 | KIM, SANGWON VINCENTSNOOK, ADAM | THOMAS JEFFERSON UNIVERSITY, PA | $218,790 | ZCA1 |
| 2024 | Genetic architecture of thyroid cancer and its clinical utility1R21CA282380-01A1 | GIGNOUX, CHRISTOPHER RPOZDEYEV, NIKITA | UNIVERSITY OF COLORADO DENVER, CO | $218,790 | ZCA1 |
| 2024 | Cultural and Linguistic Adaptation of a Breast Reconstruction Decision Tool1R21CA287321-01 | LEE, CLARA NAN-HI | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $218,162 | ZCA1 |
| 2024 | Proteomic signatures to predict drug response in cancer1R21CA288806-01 | ONG, SHAO-ENYEUNG, RAYMOND | UNIVERSITY OF WASHINGTON, WA | $218,089 | ZCA1 |
Showing the 200 most recent of 276 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.